The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Quality-adjusted life years assessment using cabozantinib for patients with advanced hepatocellular carcinoma (aHCC) in the CELESTIAL trial.
 
Ghassan K. Abou-Alfa
Consulting or Advisory Role - 3DMedcare; Agios; Alignmed; Amgen; Antengene; Aptus Clinical; ASLAN Pharmaceuticals; Astellas Pharma; AstraZeneca; Bayer; BeiGene; BiolineRx (I); Boston Scientific; BridgeBio Pharma; Bristol-Myers Squibb; CARsgen Therapeutics; CASI Pharmaceuticals; Celgene; Celsion; Cipla; CytomX Therapeutics (I); Daiichi Sankyo; Debiopharm Group; Delcath Systems; Eisai; EMD Serono (I); Exelixis; Genoscience Pharma; Gilead Sciences (I); Halozyme; Halozyme; Hengrui Pharmaceutical; Inovio Pharmaceuticals; Ipsen; Janssen (I); Jazz Pharmaceuticals; Kyowa Hakko Kirin; LAM Therapeutics; Lilly; Loxo (I); Medimmune; Merck Serono; Minapharma; Newlink Genetics (I); Novella Clinical; Onxeo; PCI Biotech; PCI Biotech; Pfizer (I); Pharmacyclics (I); Pharmacyte Biotech (I); Pieris Pharmaceuticals (I); QED Therapeutics; RedHill Biopharma; Roche; Sanofi; SERVIER; Silenseed (I); Sillajen; Sirtex Medical; Sirtex Medical; SOBI (I); Targovax (I); Tekmira; Tekmira; twoXAR; Vicus Therapeutics (I); Yakult Pharmaceutical; Yakult Pharmaceutical; Yiviva
Research Funding - Acta Biologica (Inst); Agios (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); CASI Pharmaceuticals (Inst); Celgene (Inst); Exelixis (Inst); Genentech (Inst); Halozyme (Inst); Incyte (Inst); Lilly (Inst); MabVax (Inst); MedImmune (Inst); Momenta Pharmaceuticals (Inst); Novartis (Inst); OncoMed (Inst); OncoQuest (Inst); Polaris (Inst); Puma Biotechnology (Inst); QED Therapeutics (Inst); QED Therapeutics (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Polaris
 
Patrick Mollon
Employment - Ipsen; Roche (I)
Stock and Other Ownership Interests - Novartis; Pfizer
 
Tim Meyer
Consulting or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb; Novartis
Research Funding - Bayer (Inst); BTG (Inst); Ipsen (Inst)
 
Ann-Lii Cheng
Honoraria - AstraZeneca; Bayer Yakuhin; Eisai; Genentech/Roche
Consulting or Advisory Role - AstraZeneca; Bayer Schering Pharma; Bristol-Myers Squibb; CSR Pharma; Eisai; Genentech/Roche; MSD; Novartis; Ono Pharmaceutical
 
Anthony B. El-Khoueiry
Honoraria - Bayer; Bristol-Myers Squibb; Eisai; EMD Serono; Merck; Novartis; Roche/Genentech
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; CytomX Therapeutics; Eisai; EMD Serono; Exelixis; Merck; Roche
Research Funding - Astex Pharmaceuticals; AstraZeneca
 
Robin Kate Kelley
Consulting or Advisory Role - Agios (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Debiopharm Group (Inst); Genentech/Roche; Target Pharmasolutions; Target Pharmasolutions (Inst)
Research Funding - Adaptimmune (Inst); Agios (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Exelixis (Inst); Lilly (Inst); MedImmune (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Regeneron (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Tekmira (Inst)
 
Ari David Baron
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Genentech/Roche; Lilly; Merck
 
Fawzi Benzaghou
Employment - Ipsen
 
Velichka Valerieva Valcheva
Employment - Ipsen
Stock and Other Ownership Interests - Sanofi
 
Saswati Hazra
Employment - Exelixis; Exelixis (I)
Stock and Other Ownership Interests - Exelixis
 
Milan Mangeshkar
Employment - Exelixis
Stock and Other Ownership Interests - Exelixis
 
Nicholas Freemantle
Honoraria - Abbvie; Allergan; Ipsen; Pfizer; PTC Therapeutics; Sanofi; Takeda; Tesaro
Consulting or Advisory Role - Abbvie; Allergan; Ipsen; Pfizer; PTC Therapeutics; Sanofi; Takeda; Tesaro
Speakers' Bureau - Biogen; Sanofi
Research Funding - Abbvie; Allergan; Ipsen; Pfizer; PTC Therapeutics; Sanofi; Takeda; Tesaro